Blackstone Minerals

Copper Price Update: Q2 2025 in Review

The copper price was volatile during the second quarter of 2025, but remained elevated compared to the price point near the start

Maritime Commences Construction at Hammerdown, Adds to Technical Team

Maritime Resources Corp. (TSXV: MAE,OTC:MRTMD) (‘Maritime’ or the ‘Company’) is pleased to provide an update for the Hammerdown Gold Project, located in

IBN Announces Latest Episode of The MiningNewsWire Podcast featuring Chairman Kal Malhi and CEO Paul Ténière of LaFleur Minerals Inc.

  Via IBN IBN a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release

FPX Nickel Provides Update on Normal Course Issuer Bid

     FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (‘ FPX ‘ or the ‘ Company ‘) is pleased to provide an update on

NevGold Announces Up to 92% Antimony Recovery From Positive Metallurgical Testwork Program at Oxide Gold-Antimony Limo Butte Project in Nevada

  Nevgold Corp. (‘ NevGold ‘ or the ‘ Company ‘) ( TSXV:NAU,OTC:NAUFF) (OTCQX:NAUFF) (Frankfurt:5E50 ) is pleased to announce extremely positive antimony (‘Antimony’,

Crypto Market Update: Pro-Crypto Climate Fuels Massive Jump in BTC Millionaires

Here’s a quick recap of the crypto landscape for Monday (July 23) as of 9:00 a.m. UTC. Get the latest insights on Bitcoin,

IsoEnergy and Purepoint Extend High-Grade Mineralization at the Dorado JV with a 70 Metre Step-Out Peaking at 110,800 CPS

IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) (‘IsoEnergy’) and Purepoint Uranium Group Inc. (TSXV: PTU)PTU) (OTC: PTUUF) (‘Purepoint’) are pleased to report

Nuvau’s Gold-Focused Exploration Program Underway at Matagami

Visible gold found in first hole—assays are pending Nuvau Minerals Inc. (TSXV: NMC) has launched its gold-focused exploration program at its Matagami Property

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

  Radiopharm Theranostics (ASX:RAD,OTC:RDPTF, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet